# Azurity Pharmaceuticals

Azurity Pharmaceuticals is an other based in Greenwood Village, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Greenwood Village, United States
- **Region:** North America
- **Address:** Greenwood Village, United States
- **Assets under management:** Undisclosed
- **Website:** azurity.com
- **LinkedIn:** https://www.linkedin.com/company/cutispharma-inc.

## Regulatory record

- **Reports private funds:** No

## About

Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to addressing the critical and often invisible crisis facing overlooked patients by purposefully developing and tailoring innovative pharmaceutical solutions to meet their specific, unmet needs, which are often ignored by the broader industry. By reformulating, adapting, and developing new therapies that meet specialized patient needs, we are delivering treatment alternatives that solve issues impacting patients’ day-to-day lives. With a broad portfolio of more than 50 medicines across 10 therapeutic areas fueling our mission, Azurity has the agility and velocity to provide safe, quality therapies that are reliable and easy to use.

## Sectors

- Pharmaceuticals
- Specialty Pharma

## People

- Richard Blackburn — CEO

## Questions

### What is Azurity's approach to product development?

Azurity does not discover new molecules. It identifies FDA-approved drugs where a significant patient population—often pediatrics, geriatrics, or those with dysphagia—cannot use the standard tablet form. The firm reformulates these drugs into oral liquids, sprinkle capsules, chewables, or films, and files 505(b)(2) applications that rely partially on the reference drug's existing safety data rather than conducting entirely new clinical trials.

### What therapeutic areas does Azurity focus on?

Azurity's portfolio concentrates on cardiovascular, central nervous system, and anti-infective categories. Notable products include Epaned (enalapril oral solution) for pediatric hypertension, Dyanavel XR (amphetamine) for ADHD, and Firvanq (vancomycin oral solution) for C. difficile-associated diarrhea. The Slayback acquisition added injectable and ophthalmic pipeline candidates.

### How does Azurity compete with large generic manufacturers?

Azurity targets patient populations too small to attract major generic manufacturers. Developing a liquid formulation of a drug like enalapril requires taste-masking, stability testing, and bioequivalence work that represents a niche capability set. Once approved, the limited market size and manufacturing complexity create natural barriers to entry, allowing Azurity to avoid the volume-and-price competition that defines standard generics.

### Does Azurity have international operations?

Azurity's commercial operations are concentrated in the United States. The Slayback Pharma acquisition included R&D facilities in Hyderabad, India, alongside a New Jersey-based development site, so the firm now has a transcontinental research footprint. Selling internationally remains limited, as 505(b)(2) approvals are jurisdiction-specific and many of Azurity's reference drugs have different regulatory statuses abroad.

## Related profiles

- [Provenance Capital](https://altss.com/profile/provenance-capital)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/azurity-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology